---

Liver Cirrhosis — Comprehensive Notes

---

1. Definition

• Diffuse hepatic fibrosis
• Replacement of normal liver architecture by nodules (both regenerative and fibrotic)
• Disruption of vascular relationships

Gross appearance: The liver surface is covered with bulging regenerative nodules separated by broad scars.

---

2. Etiology / Causes

Alcohol-associated cirrhosis = micronodular (<3 mm). With cessation of alcohol, larger nodules may form → mixed micro- and macronodular.

---

3. Pathogenesis

Key Cellular Players

• Normally a pericyte in the Space of Dissé (abluminal to sinusoidal endothelium)
• Upon activation → transforms into myofibroblast
• Characterized by: ↑ smooth muscle actin expression, ↑ motility/contractility, collagen type 1 production
• Earliest matrix product = fibronectin, then collagen type 1
• Activating pathways: PDGF, TGF-β, integrin signaling

• Portal fibroblasts → implicated in biliary forms of injury (PBC, PSC)
• Kupffer cells (macrophages) → release profibrogenic cytokines → activate stellate cells; some subclasses promote fibrosis, others resolve it
• Hepatocytes → epithelial cell injury (apoptosis, necrosis, inflammation) is the initiating event

Fibrosis Cascade (simplified)

Hepatocyte injury → Kupffer cell activation → cytokine release (TGF-β, PDGF)
→ Stellate cell activation → myofibroblast transformation
→ Collagen/ECM deposition → progressive fibrosis → nodule formation
→ Disruption of vascular architecture → CIRRHOSIS

Alcohol-Specific Mechanism

• Ethanol → ADH → acetaldehyde (highly reactive)
• Also via CYP2E1 (MEOS) → reactive oxygen species (ROS)
• Acetaldehyde adducts interfere with microtubule formation and protein trafficking
• ROS → Kupffer cell activation → stellate cell activation → collagen production
• Fatty acid oxidation ↓, lipoprotein secretion ↓ → steatosis
• Fibrosis: centrilobular, pericellular, or periportal → connects portal triads to central veins

---

4. Morphology

Gross

• Entire liver replaced by regenerative nodules separated by fibrous septa
• Surface nodularity easily visible
• Liver may be enlarged (early) or shrunken/small (late)
• Nodule size varies: micronodular (<3 mm, e.g., alcoholic) vs. macronodular (>3 mm, e.g., viral)

Microscopic

• Fibrous bands linking portal tracts to each other OR portal tracts to central veins
• Regenerative nodules surrounded by fibrosis
• Ductular reactions (stem cell-derived ductlike structures) increase with disease progression, most prominent in cirrhosis
• Variable degrees of parenchymal loss and vascular thrombosis (especially portal vein)

Reversibility

• Regression of fibrosis may follow disease remission/cure
• Scars become thinner, compact, then fragment
• Adjacent nodules coalesce into larger parenchymal islands
• All cirrhotic livers show elements of both progression and regression

---

5. Clinical Features

Compensated Cirrhosis (~40% asymptomatic)

• Often discovered incidentally on imaging, labs, or endoscopy
• Nonspecific: fatigue, weight loss, ↓ muscle mass, ↓ libido, sleep disturbances
• ~40% have esophageal varices (asymptomatic if not bleeding)
• Normal/near-normal liver synthetic function

Decompensated Cirrhosis (signs of organ failure)

• Ascites (most frequent sign of decompensation — present in 80%)
• Variceal hemorrhage
• Hepatic encephalopathy
• Jaundice

Physical Examination Findings

---

6. Complications

Framework

A. Portal Hypertension

• HVPG (Hepatic Venous Pressure Gradient) >10–12 mmHg → varices develop
• HVPG >12 mmHg → risk of variceal bleeding
• Mechanisms:
  • Fixed component: fibrous tissue + nodule compression of sinusoids
  • Functional component: intrahepatic NO deficiency → vasoconstriction
  • Paradox: intrahepatic NO ↓ (vasoconstriction) but extrahepatic NO ↑ (splanchnic vasodilation)
• Splanchnic vasodilation → ↑ portal inflow → maintains portal hypertension
• Systemic vasodilation → ↓ effective arterial volume → RAAS activation → Na/water retention → hyperdynamic circulation

B. Varices and Variceal Hemorrhage

• Present in ~50% of newly diagnosed cirrhosis
• Prevalence: Child A 40% → Child C 85%
• Growth rate: 7–8%/year; small varices bleed ~5%/year; large varices ~15%/year
• Predictors of hemorrhage: large varices, severe liver disease (Child C), red wale markings
• Manifestation: hematemesis, melena, or both
• Diagnosis: upper GI endoscopy (active bleed, white nipple sign, clot on varix, or varices as only source)

C. Ascites

• Most common cause of decompensation; 80% of decompensated patients
• Rate of development: 7–10%/year in compensated cirrhosis
• Pathophysiology: Sinusoidal portal hypertension → splanchnic vasodilation → ↓ effective arterial volume → RAAS activation → Na/water retention
• SAAG (Serum-Ascites Albumin Gradient):

• Paracentesis mandatory for new-onset ascites: check albumin, total protein, PMN count, culture, cytology

D. Spontaneous Bacterial Peritonitis (SBP)

• Ascites PMN count ≥250 cells/mm³ = diagnostic
• Most common organisms: E. coli, Klebsiella, Streptococcus pneumoniae
• Treatment: 3rd generation cephalosporins (e.g., cefotaxime)
• Prophylaxis: norfloxacin in high-risk patients
• Associated with 4-fold ↑ mortality

E. Hepatic Encephalopathy (HE)

• Results from portosystemic shunting + liver insufficiency → ↑ ammonia and other toxins reach brain
• Grades I–IV (West Haven criteria)
• Precipitants: GI bleed, infection, dehydration, constipation, electrolyte disturbance, sedatives
• Treatment: lactulose (reduces ammonia), rifaximin (non-absorbable antibiotic)

F. Hepatorenal Syndrome (HRS)

• Functional renal failure in advanced cirrhosis — no intrinsic kidney disease
• Type 1 (now HRS-AKI): rapid onset, sCr doubles to >2.5 mg/dL in <2 weeks
• Type 2 (now HRS-CKD): gradual, associated with refractory ascites
• Mechanism: extreme splanchnic vasodilation → renal vasoconstriction
• Treatment: terlipressin + albumin (preferred); norepinephrine + albumin; TIPS; liver transplant

G. Hepatopulmonary Syndrome

• Intrapulmonary vascular dilation → hypoxemia
• Classic: platypnea (SOB worse upright, better supine), orthodeoxia
• Diagnosis: contrast echocardiography (bubble test), 99mTc-MAA scan

H. Portopulmonary Hypertension

• Pulmonary arterial hypertension in setting of portal hypertension
• Diagnosis: right heart catheterization (mPAP ≥25 mmHg)

I. Hepatocellular Carcinoma (HCC)

• Can develop at any stage of cirrhosis; accelerates course
• Annual risk ~2–4% in cirrhotic patients
• Surveillance: liver ultrasound every 6 months ± AFP

J. Other Complications

• Hepatic hydrothorax: transdiaphragmatic movement of ascites → pleural effusion (usually right-sided)
• Cirrhotic cardiomyopathy: impaired cardiac contractile response to stress
• Coagulopathy: ↓ synthesis of clotting factors (II, V, VII, IX, X)
• Thrombocytopenia: hypersplenism, ↓ thrombopoietin
• Hyponatremia: dilutional (water retention > sodium)
• Osteoporosis: especially in cholestatic disease
• Hypogonadism, adrenal insufficiency, malnutrition

---

7. Diagnosis

Laboratory Tests

Imaging

• Ultrasound (US): Heterogeneous echogenicity, nodular surface, splenomegaly, ascites, collateral vessels — first-line
• CT scan: Nodular liver contour, varices, splenomegaly, HCC detection
• MRI/MRCP: Better soft tissue detail; useful for HCC characterization
• Transient Elastography (FibroScan): Liver stiffness >14 kPa suggests cirrhosis; >21 kPa associated with portal hypertension; <19.5 kPa — varices unlikely
• ARFI elastography: >2.6 m/sec suggests cirrhosis
• MR Elastography (MRE): Stiffness >5.9 kPa suggests cirrhosis; liver biopsy often not required

Liver Biopsy

• Gold standard for confirming cirrhosis and assessing fibrosis stage
• Required when non-invasive tests are inconclusive
• Contraindicated with significant coagulopathy (use transjugular approach)
• Fibrosis staging: Metavir F0–F4 (F4 = cirrhosis)

Non-invasive Fibrosis Markers

• FIB-4 index = (age × AST) / (platelets × √ALT)
• APRI score
• Commercial panels (FibroTest, ELF test)
• Useful for distinguishing early from late fibrosis, but not individual stages

---

8. Staging / Prognostic Scoring

Child-Pugh Score (Child-Turcotte-Pugh)

• Class B (score ≥7) = traditional criterion for liver transplant listing
• Class A = "compensated cirrhosis"

MELD Score (Model for End-Stage Liver Disease)

• Uses: INR, bilirubin, creatinine
• Modified as MELD-Na (incorporates serum sodium) for better mortality prediction
• Current standard for liver transplant organ allocation in the USA (replaced Child-Pugh)
• Higher score = higher 90-day mortality on transplant waiting list
• Online calculator: OPTN MELD calculator

PELD Score

• Used for pediatric patients (<12 years)

---

9. Natural History

• Compensated → Decompensated: ~5–7% per year
• Median time to decompensation: ~6 years from diagnosis
• 10-year probability of decompensation from compensated state: 58%
• Annual decompensation rate by etiology:
  • HCV-related: 4%/year
  • Alcohol-related: 6–10%/year (higher if actively drinking)
  • HBV-related: 10%/year

Survival

• Compensated cirrhosis: median survival 9–12 years
• Decompensated cirrhosis: median survival ~2 years
• Overall 5-year survival: ~38%; 10-year: ~22% (Danish population study)
• Patients with infection: 4× ↑ mortality
• Patients with renal failure: 7–8× ↑ mortality

---

10. Treatment

General Principles

• Treat the underlying cause (most important to slow/reverse fibrosis):
  • HCV → direct-acting antivirals (cure possible → regression of fibrosis)
  • HBV → nucleos(t)ide analogs (entecavir, tenofovir)
  • Alcohol → abstinence (mandatory)
  • MASLD/NASH → weight loss, metabolic control
  • PBC → ursodeoxycholic acid (UDCA) 13–15 mg/kg/day
  • Autoimmune hepatitis → corticosteroids ± azathioprine
  • Hemochromatosis → phlebotomy
  • Wilson's disease → penicillamine / trientine

Compensated Cirrhosis Management

• HCC surveillance: Liver US ± AFP every 6 months
• Variceal screening: Upper endoscopy at diagnosis; repeat every 1–3 years if no varices
• Non-selective beta-blockers (propranolol, nadolol, carvedilol) for medium/large varices — reduce portal pressure
• Endoscopic band ligation (EBL): Primary prophylaxis for large varices
• Immunizations: HAV, HBV, pneumococcal, influenza, COVID-19
• Statins: Use in chronic viral hepatitis → reduced risk of decompensation and mortality
• Avoid NSAIDs, aminoglycosides
• Acetaminophen ≤2 g/day acceptable
• Alcohol abstinence
• Weight loss reduces portal pressure

Decompensated Cirrhosis Management

Ascites

• Grade 1 (mild): Sodium restriction (<2 g/day)
• Grade 2 (moderate): Spironolactone (100–400 mg/day) ± furosemide (40–160 mg/day)
• Grade 3 (large/tense): Large-volume paracentesis (LVP) + IV albumin (6–8 g per liter removed)
• Refractory ascites: TIPS (transjugular intrahepatic portosystemic shunt) or repeated LVP

Variceal Hemorrhage

• Acute bleeding:
  • IV terlipressin (preferred) or octreotide/somatostatin
  • Endoscopic band ligation (EBL) within 12 hours
  • IV antibiotics (ceftriaxone) — reduce risk of SBP and improve survival
  • Consider early TIPS (pre-emptive TIPS) in Child C patients
• Secondary prophylaxis: NSBB + EBL (combination)
• Primary prophylaxis (large varices): NSBB or EBL

Hepatic Encephalopathy

• Identify and treat precipitants
• Lactulose — titrate to 2–3 soft stools/day
• Rifaximin 550 mg BID — secondary prophylaxis; reduces recurrence by ~58%
• Adequate protein intake (1.2–1.5 g/kg/day; do NOT restrict protein)
• BCAA supplements in refractory cases

Spontaneous Bacterial Peritonitis

• IV cefotaxime 2 g q8h × 5 days
• IV albumin 1.5 g/kg on day 1, 1 g/kg on day 3 → prevents HRS
• Long-term prophylaxis: norfloxacin 400 mg/day or trimethoprim-sulfamethoxazole

Hepatorenal Syndrome

• Terlipressin + albumin (1st line where available)
• Norepinephrine + albumin (in ICU setting)
• Discontinue diuretics, nephrotoxins
• TIPS as bridge; liver transplantation = definitive treatment

Liver Transplantation

• Definitive therapy for end-stage cirrhosis
• Indications: MELD ≥15, Child-Pugh class B/C, refractory complications
• Contraindications: active alcohol/substance use (usually requires 6-month sobriety), extrahepatic malignancy, severe cardiopulmonary disease
• 5-year post-transplant survival: ~70–80%
• Milan criteria for HCC: single nodule ≤5 cm OR up to 3 nodules ≤3 cm, no vascular invasion, no extrahepatic spread

Acute-on-Chronic Liver Failure (ACLF)

• Defined as acute decompensation of cirrhosis with organ failure
• Precipitants: bacterial infection, GI bleeding, alcohol-associated hepatitis, reactivation of HBV
• Management: treat precipitant, organ support, consider LT
• G-CSF + erythropoietin combination shown to reduce mortality in some studies
• Prognosis poor with multiple organ failures

---

11. Fibrosis Reversal

• Hepatitis C cure with DAAs → demonstrated fibrosis regression/reversal
• HBV suppression → fibrosis regression
• Abstinence from alcohol → regression in some patients
• Mechanisms: macrophage-mediated matrix degradation, stellate cell deactivation/apoptosis, scar remodeling
• Fibrous septa become thinner, denser, then fragment; nodules coalesce

---

12. Summary Table

---

• Robbins & Kumar Basic Pathology, p. 598
• Sleisenger and Fordtran's GI and Liver Disease, Ch. 74
• Goldman-Cecil Medicine, Ch. 139
• Harrison's Principles of Internal Medicine 22e, Ch. 355 & 347
• Yamada's Textbook of Gastroenterology, 7th ed.